...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Platelet-Derived Thrombogenicity Measured by Total Thrombus-Formation Analysis System in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
【24h】

Platelet-Derived Thrombogenicity Measured by Total Thrombus-Formation Analysis System in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

机译：血小板衍生的血栓形成性通过总血栓形成分析系统测量的ST段抬高心肌梗死患者进行一次经皮冠状动脉介入

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Prompt and potent antiplatelet effects are important aspects of management of ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI). We evaluated the association between platelet-derived thrombogenicity during PPCI and enzymatic infarct size in STEMI patients. Methods?and?Results: Platelet-derived thrombogenicity was assessed in 127 STEMI patients undergoing PPCI by: (1) the area under the flow-pressure curve for the PL-chip (PLsub18/sub-AUCsub10/sub) using the total thrombus-formation analysis system (T-TAS); and (2) P2Ysub12/subreaction units (PRU) using the VerifyNow system. Patients were divided into 2 groups (High and Low) based on median PLsub18/sub-AUCsub10/subduring PPCI. PRU levels during PPCI were suboptimal in both the High and Low PLsub18/sub-AUCsub10/subgroups (median [interquartile range] 266 [231–311] vs. 272 [217–317], respectively; P=0.95). The percentage of final Thrombolysis in Myocardial Infarction (TIMI) 3 flow was lower in the High PLsub18/sub-AUCsub10/subgroup (75% vs. 90%; P=0.021), whereas corrected TIMI frame count (31.3±2.5 vs. 21.0±2.6; P=0.005) and the incidence of slow-flow/no-reflow phenomenon (31% vs. 11%, P=0.0055) were higher. The area under the curve for creatine kinase (AUCsubCK/sub) was greater in the High PLsub18/sub-AUCsub10/subgroup (95,231±7,275 IU/L h vs. 62,239±7,333 IU/L h; P=0.0018). Multivariate regression analysis identified high PLsub18/sub-AUCsub10/subduring PPCI (β=0.29, P=0.0006) and poor initial TIMI flow (β=0.37, P0.0001) as independent determinants of AUCsubCK/sub. Conclusions: T-TAS-based high platelet-derived thrombogenicity during PPCI was associated with enzymatic infarct size in patients with STEMI.
机译：背景：提示和有效的抗血小板效应是在经皮冠状动脉介入（PPCI）的ST升高心肌梗死（STEMI）患者的重要方面。我们评估了在STEMI患者的PPCI和酶促诱导术期间血小板衍生的血栓形成性之间的关系。方法？结果：在接受PPCI的127次催眠患者中评估血小板衍生的血栓形成性：（1）PL-Chip（PL 18 -Auc 10 ）使用总血栓形成分析系统（T-TAS）; （2）P2Y 12 反应单元（PRU）使用verifyNow系统。基于中位数PL 18 / sum> -auc 10 在PPCI期间，将患者分为2组（高低）。 PPCI期间的PRU水平在高和低PL 18 -auc 10 组（中值[四分位数范围] 266 [231-311]与272 [217- 317]分别; p = 0.95）。高PL <亚次> 18℃下的心肌梗死（TIMI）3流动的最终溶栓百分比较低（75％vs.90％; P = 0.021） ，而校正的TIMI帧数（31.3±2.5与21.0±2.6; p = 0.005）和慢速/无回流现象的发生率（31％vs.11％，p = 0.0055）。在高pL 18 -auc 10 组（95,231±7,275 iu /）中，肌酸激酶曲线下的区域更大L H对62,239±7,333 IU / L H; P = 0.0018）。多变量回归分析鉴定了PPCI（β= 0.29，P = 0.0006）期间高PL 18 -auc 10 初始初始钟线（β= 0.37，p <0.0001） AUC CK 的独立决定因素。结论：PPCI期间基于TAS基的高血小板衍生的血栓形成性与Stemi患者的酶促梗塞大小有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号